STAA Key Statistics, Chart & Performance
The current stock price of STAA is 22.105 USD. In the past month the price decreased by -12.19%. In the past year, price decreased by -3.11%.
STAA Latest News, Press Relases and Analysis
STAA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.28 | 16.65B | ||
| SOLV | SOLVENTUM CORP | 14.23 | 14.66B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.24 | 11.96B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 24.83 | 5.48B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.72 | 4.63B | ||
| HAE | HAEMONETICS CORP/MASS | 17.32 | 3.89B | ||
| ICUI | ICU MEDICAL INC | 19.13 | 3.76B | ||
| XRAY | DENTSPLY SIRONA INC | 7.84 | 2.47B | ||
| UFPT | UFP TECHNOLOGIES INC | 28.54 | 1.90B | ||
| NEOG | NEOGEN CORP | 24.58 | 1.60B | ||
| EMBC | EMBECTA CORP | 4.14 | 719.97M | ||
| BVS | BIOVENTUS INC - A | 12.9 | 629.80M |
Related stock screener links
About STAA
Company Profile
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Company Info
STAAR SURGICAL CO
1911 Walker Ave
Monrovia California CALIFORNIA 92630 US
CEO: Caren Mason
Employees: 1157
Phone: 16263037902
STAAR SURGICAL CO / STAA FAQ
What does STAA do?
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Can you provide the latest stock price for STAAR SURGICAL CO?
The current stock price of STAA is 22.105 USD. The price decreased by -0.79% in the last trading session.
Does STAA stock pay dividends?
STAA does not pay a dividend.
How is the ChartMill rating for STAAR SURGICAL CO?
STAA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for STAA stock?
The Revenue of STAAR SURGICAL CO (STAA) is expected to decline by -24.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for STAA stock?
STAAR SURGICAL CO (STAA) currently has 1157 employees.
Can you provide the upcoming earnings date for STAAR SURGICAL CO?
STAAR SURGICAL CO (STAA) will report earnings on 2026-02-09, after the market close.
STAA Technical Analysis
STAA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to STAA. While STAA has a great health rating, there are worries on its profitability.
STAA Financial Highlights
Over the last trailing twelve months STAA reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS decreased by -223.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.12% | ||
| ROE | -27.24% | ||
| Debt/Equity | 0 |
STAA Forecast & Estimates
14 analysts have analysed STAA and the average price target is 25.82 USD. This implies a price increase of 16.8% is expected in the next year compared to the current price of 22.105.
For the next year, analysts expect an EPS growth of -471.53% and a revenue growth -24.86% for STAA